Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2

Cancer immunotherapies under development have generally focused on either stimulating T-cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). We find that a combination of an anti-tumor antigen antibody...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Cell
Auteurs principaux: Zhu, Eric F., Gai, Shuning A., Opel, Cary F., Kwan, Byron H., Surana, Rishi, Mihm, Martin C., Kauke, Monique J., Moynihan, Kelly D., Angelini, Alessandro, Williams, Robert T., Stephan, Matthias T., Kim, Jacob S., Yaffe, Michael B., Irvine, Darrell J., Weiner, Louis M., Dranoff, Glenn, Wittrup, K. Dane
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4398916/
https://ncbi.nlm.nih.gov/pubmed/25873172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2015.03.004
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires